Susan B Nichols — In the News — ViroCell Biologics

ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).

The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, viral vectors, Susan B Nichols, ViroCell, The Pharma Letter

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, gene therapy, cell therapy, ViroCell, Pharmtech Focus, clinical trials, cell and gene therapies, CDMO, Susan B Nichols, viral vectors

In the news

London New York